Findings from a postmarketing observational study showed an increased risk of GBS during the 42 days following vaccination.

Pfizer's Phase 3 CREST trial results highlight the efficacy of sasanlimab combined with BCG in treating high-risk non-muscle invasive bladder cancer.

This week, the FDA granted priority review status to J&J’s JNJ application seeking approval of key pipeline candidate ...

Practice of medicine could fundamentally change with these types of therapies,” said CEO Jaideep Dudani, of T cell engagers ...